HEPATITIS B
Technical University of Munich: Therapeutic vaccine for hepatitis B enters first clinical trial
TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient was enrolled in June 2025 and treated with the vaccine. In a previous trial in healthy volunteers, the vaccine demonstrated a favorable safety profile and triggered the desired immune responses.
Saint Louis University Medical Center: Running interference: Scientists block viral RNA, aim to cure hepatitis B
Scientists reported that a class of drugs, called RNA interference (RNAi) therapeutics, represent a major advancement in the treatment of chronic HBV infections, expanding treatment strategies by addressing viral antigens, silencing the virus and helping to reinvigorate the body’s immune response. The drugs will most likely be given to patients in combination with other medications, and researchers hope that their addition to drug combination therapies will bring us closer to a functional cure.
HEPATITIS C
Johns Hopkins Medicine: New study finds evidence of hepatitis C virus in cells lining human brain
New findings confirmed previous studies that reported higher than usual hepatitis C (HCV) prevalence in people with schizophrenia or bipolar disorder, and suggested that HCV infections may be associated with the cause of disease rather than behaviors such as intravenous drug use.
Contagion Live: Frequent hepatitis C testing among PWID found to be cost-effective, study finds
Study findings underscored the cost-effectiveness of more frequent hepatitis C testing among people who inject drugs (PWID), compared to less frequent or no testing at all.
Contagion Live: Biannual hepatitis C testing could reduce infections among people who inject drugs
A study concluded that while frequent testing, combined with treatment, reduces the disease burden among people who inject drugs (PWID), it is not sufficient alone to achieve HCV elimination goals among PWID without broader efforts to improve access and integration of care.
CATIE: Large study finds many benefits arise from curing hepatitis C virus
Canadian researchers reviewed health indicators of more than 22,000 people who had hepatitis C. Those treated and cured had a lower risk of kidney, heart, stroke and neurocognitive issues. The findings demonstrated the broader health benefits of hepatitis C treatment beyond the liver.
POZ: Hepatitis C cure rates are high regardless of provider type
Primary care providers and nurse practitioners achieved long-term outcomes similar to those of liver disease specialists.
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.